cas 625-36-5|| where to buy 3-chloropropanoyl chloride

Nom du produit:3-chloropropanoyl chloride

IUPAC Name:3-chloropropanoyl chloride

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM326224-1000g	1-2 Weeks	ǤǤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Notes supplémentaires

Verification code*

refresh

: N° CAS:625-36-5; Formule moléculaire:C3H4Cl2O; Point de fusion:-; Code SMILES:O=C(Cl)CCCl; Densité:

: Numéro de catalogue:CM326224; Poids moléculaire:126.96; Point d'ébullition:; N° Mdl:MFCD00000747; Stockage:Keep in a tight container and store in a cool place

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Belzutifan; On September 19, MSD announced that the U.S. FDA has accepted and granted priority review for a supplemental new drug application (sNDA) seeking approval for Welireg (Belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC). Welireg was the first HIF-2α inhibitor therapy approved in the U.S. and is currently approved for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.